We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Avantor a Buy as Revival Progress Faces Persistent Margin Pressure?
Read MoreHide Full Article
Key Takeaways
Avantor's Revival helped VWR return to 1.7% organic growth in Q2 2026, ahead of expectations.
BMP revenue fell 5.6%, but double-digit order growth and a 1.1x book-to-bill signal healthier demand.
Gross margin fell to 31.7% and adjusted operating margin to 13.3%, even as 2026 guidance improved.
Avantor, Inc. (AVTR - Free Report) is showing clearer signs that its Revival program is improving execution. VWR returned to growth sooner than expected, Bioscience & Medtech Products orders strengthened and management raised its 2026 outlook.
The recovery is not complete. Earnings remain pressured, margins have contracted and the product segment has yet to translate healthier orders into sustained revenue growth. That mix makes AVTR a selective investment case rather than a clear-cut bullish story.
Avantor's Revival Starts to Lift VWR Growth
VWR Distribution & Services posted 1.7% organic growth in the second quarter of 2026, returning to positive growth ahead of management's expectations. Higher volumes and stronger commercial execution were the main drivers.
Avantor strengthened large global customer relationships, accelerated contract onboarding and improved e-commerce activity after relaunching vwr.com. Direct traffic, conversion and daily sales improved as the quarter progressed, showing that Revival initiatives are producing measurable gains.
AVTR's BMP Orders Improve Before Revenue Does
Bioscience & Medtech Products (BMP) remained the weak spot, with organic revenues down 5.6% year over year. Fluid Handling and NuSil declined in the mid-teens, while Research & Specialty Chemicals fell in the mid-single digits.
BMP delivered double-digit order growth and a 1.1 times book-to-bill ratio, with healthy orders across all business units. Management expects organic growth to return in the second half of 2026, but order strength still needs to convert into sustained sales.
Image Source: Zacks Investment Research
Avantor's Margins Keep the Recovery in Check
Second-quarter gross margin fell about 120 basis points to 31.7%. Adjusted operating margin contracted 170 basis points to 13.3%, as lower volumes, unfavorable mix, inflation and higher freight costs pressured profitability.
A revenue recovery will have limited earnings impact without better operating leverage. Thermo Fisher Scientific (TMO - Free Report) , which serves laboratory and biopharma workflows through technologies, purchasing channels and pharmaceutical services, is a relevant competitive reference point as Avantor works to strengthen customer retention.
AVTR's 2026 Outlook Improves but Earnings Stay Soft
Avantor raised its 2026 organic revenue growth outlook to negative 0.5% to positive 0.5% and lifted adjusted earnings per share guidance to 80-83 cents. The increase reflects better second-quarter performance and stronger second-half expectations for VWR.
The Zacks model still projects about 0.4% revenue growth for 2026 and a 10.7% decline in adjusted earnings per share. Agilent Technologies (A - Free Report) , which supplies instruments, software, consumables and services across life-science, diagnostics and applied markets, provides another useful industry benchmark for Avantor's recovery.
Image Source: Zacks Investment Research
Avantor's Balance Sheet Offers Some Flexibility
Avantor ended the second quarter with about $307 million in cash and total debt of roughly $3.7 billion. Adjusted net leverage stood at 3.3 times, leaving the balance sheet improved but still moderately leveraged.
The company repaid $112.1 million of debt during the quarter and continues to prioritize excess free cash flow for debt reduction. Continued deleveraging can add flexibility, although progress also depends on sustained cash generation.
AVTR's Buy Signal Faces Weak Style Scores
Avantor's operating progress supports a more constructive view, but the evidence remains mixed. VWR is recovering, BMP orders are improving and guidance moved higher, while earnings and margins remain under pressure.
The stock currently carries a Zacks Rank #2 (Buy), a favorable near-term signal. Zacks Style Scores are most supportive at A or B, so AVTR's Value Score of C, Growth Score of D, Momentum Score of F and VGM Score of D do not reinforce the Rank. The split supports a selective stance while the recovery develops.
View the Zacks #1 Rank List
Image: Bigstock
Is Avantor a Buy as Revival Progress Faces Persistent Margin Pressure?
Key Takeaways
Avantor, Inc. (AVTR - Free Report) is showing clearer signs that its Revival program is improving execution. VWR returned to growth sooner than expected, Bioscience & Medtech Products orders strengthened and management raised its 2026 outlook.
The recovery is not complete. Earnings remain pressured, margins have contracted and the product segment has yet to translate healthier orders into sustained revenue growth. That mix makes AVTR a selective investment case rather than a clear-cut bullish story.
Avantor's Revival Starts to Lift VWR Growth
VWR Distribution & Services posted 1.7% organic growth in the second quarter of 2026, returning to positive growth ahead of management's expectations. Higher volumes and stronger commercial execution were the main drivers.
Avantor strengthened large global customer relationships, accelerated contract onboarding and improved e-commerce activity after relaunching vwr.com. Direct traffic, conversion and daily sales improved as the quarter progressed, showing that Revival initiatives are producing measurable gains.
AVTR's BMP Orders Improve Before Revenue Does
Bioscience & Medtech Products (BMP) remained the weak spot, with organic revenues down 5.6% year over year. Fluid Handling and NuSil declined in the mid-teens, while Research & Specialty Chemicals fell in the mid-single digits.
BMP delivered double-digit order growth and a 1.1 times book-to-bill ratio, with healthy orders across all business units. Management expects organic growth to return in the second half of 2026, but order strength still needs to convert into sustained sales.
Image Source: Zacks Investment Research
Avantor's Margins Keep the Recovery in Check
Second-quarter gross margin fell about 120 basis points to 31.7%. Adjusted operating margin contracted 170 basis points to 13.3%, as lower volumes, unfavorable mix, inflation and higher freight costs pressured profitability.
A revenue recovery will have limited earnings impact without better operating leverage. Thermo Fisher Scientific (TMO - Free Report) , which serves laboratory and biopharma workflows through technologies, purchasing channels and pharmaceutical services, is a relevant competitive reference point as Avantor works to strengthen customer retention.
AVTR's 2026 Outlook Improves but Earnings Stay Soft
Avantor raised its 2026 organic revenue growth outlook to negative 0.5% to positive 0.5% and lifted adjusted earnings per share guidance to 80-83 cents. The increase reflects better second-quarter performance and stronger second-half expectations for VWR.
The Zacks model still projects about 0.4% revenue growth for 2026 and a 10.7% decline in adjusted earnings per share. Agilent Technologies (A - Free Report) , which supplies instruments, software, consumables and services across life-science, diagnostics and applied markets, provides another useful industry benchmark for Avantor's recovery.
Image Source: Zacks Investment Research
Avantor's Balance Sheet Offers Some Flexibility
Avantor ended the second quarter with about $307 million in cash and total debt of roughly $3.7 billion. Adjusted net leverage stood at 3.3 times, leaving the balance sheet improved but still moderately leveraged.
The company repaid $112.1 million of debt during the quarter and continues to prioritize excess free cash flow for debt reduction. Continued deleveraging can add flexibility, although progress also depends on sustained cash generation.
AVTR's Buy Signal Faces Weak Style Scores
Avantor's operating progress supports a more constructive view, but the evidence remains mixed. VWR is recovering, BMP orders are improving and guidance moved higher, while earnings and margins remain under pressure.
The stock currently carries a Zacks Rank #2 (Buy), a favorable near-term signal. Zacks Style Scores are most supportive at A or B, so AVTR's Value Score of C, Growth Score of D, Momentum Score of F and VGM Score of D do not reinforce the Rank. The split supports a selective stance while the recovery develops.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.